Soft tissue sarcomas are the sixth most common cancer in children and collectively account for about seven percent of all pediatric cancers. The development of increasingly intensive, multimodality treatment protocols for these tumors has led to a steady increase in cure rates for these neoplasms, especially for rhabdomyosarcoma, the most common pediatric soft tissue sarcoma. This article provides an overview of the basic biology, clinical management, and clinical research for pediatric soft tissue sarcomas.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
50% Article relates to my practice (1/2)
0% Article does not relate to my practice (0/2)
50% Undecided (1/2)
2

Will this article lead to more cost-effective healthcare?

0% Yes (0/2)
50% No (1/2)
50% Undecided (1/2)
3

Was this article biased? (commercial or personal)

0% Yes (0/2)
50% No (1/2)
50% Undecided (1/2)
4

What level of evidence do you think this article is?

0% Level 1 (0/2)
0% Level 2 (0/2)
100% Level 3 (2/2)
0% Level 4 (0/2)
0% Level 5 (0/2)